SCHEMBL4866883

SCHEMBL4866883

Nc1cccnc1N1CCC[C@H]2CCCC[C@@H]21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK1 P23458 1/20 0.43
JAK3 P52333 1/20 0.43
GRIN2D O15399 1/20 0.41
GRIN3B O60391 1/20 0.41
GRIN1 Q05586 1/20 0.41
GRIN2A Q12879 1/20 0.41
GRIN2B Q13224 1/20 0.41
GRIN2C Q14957 1/20 0.41
GRIN3A Q8TCU5 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
SMARCA2 P51531 2/20 0.40
SMARCA4 P51532 2/20 0.40
PBRM1 Q86U86 2/20 0.40
NR1I2 O75469 1/20 0.40
NR1H2 P55055 1/20 0.40
MAPK13 O15264 1/20 0.39
MAPK12 P53778 1/20 0.39
MAPK11 Q15759 1/20 0.39
MAPK14 Q16539 1/20 0.39
CSF1R P07333 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4865463 1.00 JAK1 (0.43) JAK1JAK3GRIN2DGRIN3BGRIN1
SCHEMBL4865454 1.00 JAK1 (0.43) JAK1JAK3GRIN2DGRIN3BGRIN1
SCHEMBL4865461 1.00 JAK1 (0.43) JAK1JAK3GRIN2DGRIN3BGRIN1
SCHEMBL6220849 1.00 JAK1 (0.43) JAK1JAK3GRIN2DGRIN3BGRIN1
SCHEMBL4866890 1.00 JAK1 (0.43) JAK1JAK3GRIN2DGRIN3BGRIN1
SCHEMBL3950324 0.80 JAK3 (0.48) JAK3GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL20336407 0.73 ALDH1A1 (0.42) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL22587517 0.73 GRIN2D (0.48) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL29445489 0.73 GRIN2D (0.48) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL2825683 0.70 HRH3 (0.51) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7361662-B2 Pyridopyrimidinone compounds, method for production thereof and medicaments comprising the same LES LABORATOIRES SERVIER (FR) 2008-04-22 US disclosed
EP-1560826-B1 PYRIDOPYRIMIDINONE COMPOUNDS, METHOD FOR PRODUCTION THEREOF AND MEDICAMENTS COMPRISING THE SAME SERVIER LAB (FR) 2006-04-12 EP disclosed
US-20050288311-A1 Pyridopyrimidinone compounds, method for production thereof and medicaments comprising the same LES LABORATOIERS SERVIER (FR) 2005-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288311-A1 Pyridopyrimidinone compounds, method for production thereof and medicaments comprising the same MAP4K2, PLK2, MAP4K3 JAK1 10/4885JAK3 40/4885GRIN2D 1759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.